Kynos Therapeutics completes Phase I trials for KNS366, a KMO inhibitor for inflammatory conditions.
Kynos Therapeutics, a life sciences spin-out from the University of Edinburgh, has completed Phase I trials for its drug candidate KNS366, a KMO inhibitor, demonstrating safety, tolerability, and effective targeting of the enzyme KMO. The drug aims to treat acute and chronic inflammatory conditions by preventing tissue damage and immune system dysregulation during inflammation.
April 22, 2024
5 Articles